Ind-Swift Laboratories Ltd. (NSE: INDSWFTLAB, BSE: 532305) is a Manimajra, Chandigarh-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹3,158 Cr, it ranks #1,034 by market cap among the 6,197 Indian listed companies on FinBizNet, and #33 of 86 in Medicinal Chemicals and Botanical Products. At ₹363.95 (as of 16 Nov 2026), the share price is 14.7% below its 52-week high of ₹426.60 and 312.9% above its 52-week low of ₹88.15. The share price is up 257.4% over one year and up 21.8% over three months.
| Current Price | ₹363.95 |
|---|---|
| Market Cap | ₹3,158 Cr |
| NSE Symbol | INDSWFTLAB |
| BSE Code | 532305 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 71.4 |
| Return on Equity | 3.24% |
| Return on Assets | 0.66% |
| 52-Week Range | ₹88.15 – ₹426.60 |
| 1-Year Price Change | +257.4% |
| 3-Month Price Change | +21.8% |
| Beta (1Y) | 0.78 |
| Dividend Yield | 0.00% |
| Headquarters | Manimajra, Chandigarh |
| Website | www.indswiftlabs.com |
| Revenue | ₹240 Cr |
|---|---|
| Net Profit | ₹34 Cr |
| Net Margin | 14.2% |
| EPS (Basic) | ₹3.94 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Ind-Swift Laboratories Ltd. reported revenue of ₹240 Cr in Q2 FY27, up 57.5% from ₹153 Cr in Q2 FY26 and up 25.6% from ₹191 Cr in Q1 FY27. It posted a net profit of ₹34 Cr for the quarter, against a net profit of ₹8 Cr in Q2 FY26 (up 328.3%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹138 Cr (Q4 FY25) to ₹240 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹240 Cr | ₹34 Cr | 14.2% |
| Q1 FY27 | ₹191 Cr | ₹25 Cr | 12.9% |
| Q4 FY26 | ₹170 Cr | ₹15 Cr | 8.9% |
| Q3 FY26 | ₹151 Cr | ₹10 Cr | 6.3% |
| Q2 FY26 | ₹153 Cr | ₹8 Cr | 5.2% |
| Q1 FY26 | ₹153 Cr | ₹9 Cr | 5.7% |
| Q4 FY25 | ₹138 Cr | ₹222 Cr | 160.8% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 42.93% of Ind-Swift Laboratories Ltd.'s shares as of Sept 2026, against 39.50% in Dec 2025 (+3.43 percentage points). Delivery averaged 44.5% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson’s disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimuscarinic, antimigraine, and thrombocytopenia. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, azithromycin dihydrate, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride,
1. Pharmaceutical Business-This segment develops, manufactures, and sells active pharmaceutical ingredients.
1. Pharmaceutical Business-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Ind-Swift Laboratories Ltd. | ₹3,158 Cr | 71.4 | 3.24% | ₹240 Cr | +257.4% |
Listed by market capitalisation. Ratios are shown for context only.
Ind-Swift Laboratories Ltd. is trading at ₹363.95, with a market capitalisation of ₹3,158 Cr.
Ind-Swift Laboratories Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Ind-Swift Laboratories Ltd. has a P/E of 71.4 and a return on equity of 3.24%.
Ind-Swift Laboratories Ltd. is listed on the NSE under the symbol INDSWFTLAB and on the BSE under the scrip code 532305.
Ind-Swift Laboratories Ltd.'s share price is up 257.4% over one year and up 21.8% over three months. Its 52-week range is ₹88.15 to ₹426.60.
In Q2 FY27, Ind-Swift Laboratories Ltd. reported revenue of ₹240 Cr and net profit of ₹34 Cr, with basic EPS of ₹3.94 (consolidated, parsed from the company's exchange filing).
Ind-Swift Laboratories Ltd. reported revenue of ₹240 Cr in Q2 FY27, up 57.5% from ₹153 Cr in Q2 FY26 and up 25.6% from ₹191 Cr in Q1 FY27.
Promoters held 42.93% of Ind-Swift Laboratories Ltd.'s shares as of Sept 2026, against 39.50% in Dec 2025 (+3.43 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.